ARTBIO is a technology company.
ARTBIO has raised $243.0M across 3 funding rounds.
Key people at ARTBIO.
ARTBIO has raised $243.0M in total across 3 funding rounds.
ARTBIO has raised $243.0M in total across 3 funding rounds.
ARTBIO's investors include Alumni Ventures, B Capital Group, F-Prime Capital Partners, Perceptive Advisors, Sofinnova Investments, Third Rock Ventures, venBio, Adrien Cohen.
Key people at ARTBIO.
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing alpha radioligand therapies (ARTs) to redefine cancer care by precisely targeting and killing tumors while sparing healthy tissue.[1][2][3] It builds therapies using the alpha-emitting isotope Pb-212 paired with tumor-specific ligands, serves cancer patients (e.g., those with metastatic castration-resistant prostate cancer), and solves key limitations in existing radioligand therapies like lower efficacy of beta-emitters and supply chain bottlenecks for short-lived isotopes.[2][3][4][6] With strong growth momentum, ARTBIO raised $23 million in seed funding in 2023, completed a $132 million Series B, secured FDA clearance for its lead program AB001's IND, and is advancing a differentiated pipeline supported by proprietary manufacturing.[2][3][5]
ARTBIO was founded in 2021 in Norway (with operations in Cambridge, Oslo, London, and Basel) by scientific pioneers Roy Larsen and Øyvind Bruland, alongside Radforsk and F-Prime Capital.[1][2][3] Larsen and Bruland, rooted in nearly a century of radiation therapy research at the University of Oslo and Norway's Radium Hospital (with lineage to Marie Curie), previously invented Xofigo—the first metabolically targeted alpha therapy, later acquired by Bayer via Algeta.[2][3][5] The idea emerged from their expertise in alpha emitters, aiming to pair optimal Pb-212 isotopes with proven tumor targets while building a new manufacturing ecosystem to address production and distribution challenges for short half-life therapies.[3][6] Early traction included a $23 million seed round in June 2023 led by F-Prime Capital and Omega Funds, launching ARTBIO publicly.[3]
ARTBIO stands out in radiopharmaceuticals through its patient-centric, holistic approach to ARTs, emphasizing four pillars: differentiated pipeline, isotope production, distributed manufacturing, and expert execution.[2][6]
ARTBIO rides the surging radiopharmaceutical trend, where radioligand therapies (RLTs) market is expanding due to precision oncology demands, with alpha-emitters gaining traction over beta-emitters for better tumor kill rates and safety.[3][6] Timing aligns with maturing infrastructure for short-lived isotopes and investor enthusiasm—evidenced by its $155M+ total funding amid a biotech funding rebound—plus regulatory wins like FDA IND clearance.[2][5] Favorable forces include abundant nuclear stockpiles for Pb-212, partnerships de-risking supply chains, and a shift from rigid centralized production to distributed models, enabling broader patient access.[5][6] ARTBIO influences the ecosystem by pioneering scalable ART manufacturing, potentially accelerating alpha therapy adoption and inspiring similar networks for next-gen radiopharma.
ARTBIO is poised to advance its ART pipeline, with AB001 progressing through prostate cancer trials and additional programs targeting deadly cancers, fueled by Series B proceeds for manufacturing expansion and supply chain buildout.[2][5] Trends like AI-optimized targeting, global isotope access improvements, and combo therapies with immunotherapies will shape its path, amplifying ARTs' role in solid tumor treatment. Its influence may evolve from innovator to ecosystem leader, standardizing distributed production and pressuring competitors to match its precision and scale—ultimately transforming cancer care as its scientific legacy promises.[2][3][5] This positions ARTBIO as a high-momentum player in precision oncology's next wave.
ARTBIO has raised $243.0M across 3 funding rounds. Most recently, it raised $130.0M Series B in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $130.0M Series B | Alumni Ventures, B Capital Group, F-Prime Capital Partners, Perceptive Advisors, Sofinnova Investments, Third Rock Ventures, venBio, Adrien Cohen | |
| Dec 1, 2023 | $90.0M Series A | B Capital Group, F-Prime Capital Partners, Sofinnova Investments, Third Rock Ventures | |
| Jun 1, 2023 | $23.0M Seed | B Capital Group, F-Prime Capital Partners, Sofinnova Investments, Third Rock Ventures |
